Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

Healthsouth: Off The Sick List?

Inside Wall Street


In 1998, many health-care stocks suffered acute attacks, from write-offs and losses. Six months ago, shares of Healthsouth (HRC) were flying, at 30 a share: By Oct. 7, they had tumbled to 7 11/16. In September, many big stakeholders, including Fidelity Investments, dumped a big chunk of their stakes in the No. 1 company in outpatient surgery and rehab services.

Enter the hardy, health-care investment pros, who have started buying--including David Talbot, managing director of Health/Vest Advisors. "This is the time to buy," Talbot insists. By Nov. 10, Healthsouth had risen to 12.

Back in early September, Healthsouth stock dropped when analysts cut their earnings estimates. True enough, the company conceded on Sept. 30 that earnings growth would slow--from 30% a year to about 15% to 20%--mainly because the managed-care companies were pressuring their service providers for lower rates.

Talbot points out that Healthsouth, at its current depressed price, is a very compelling buy--based just on its projected 15%-to-20% earnings growth. Some analysts reinstated their buy ratings when third-quarter earnings came up to expectations. Talbot says that, at its price-earnings ratio of about 9, based on 1999 estimated earnings of $1.10, the stock is "definitely cheap."

Joseph Chiarelli, an analyst at J.P. Morgan Securities, who rates the stock a buy, figures that Healthsouth will generate 1999 cash flow of $1.4 billion. After funding internal growth and capital expenses, the company should have free cash flow of $100 million to $200 million, he figures.BY GENE G. MARCIALReturn to top

Return to top

blog comments powered by Disqus